Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Change in Receivables came in at $5.2 million in Q1 2026, down 11.33% YoY from $5.9 million in Q1 2025, and up 294.19% on a QoQ basis from -$2.7 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Change in Receivables data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Change in Receivables fell 11.33% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 11.77% YoY) and the FY2025 annual result came in at $10.6 million, up 773.15% from the prior year.
- Change in Receivables grew to $5.2 million in Q1 2026, from -$2.7 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $15.7 million in Q3 2023 to a low of -$6.8 million in Q4 2023.
- A 5-year average of $2.3 million and a median of $1.8 million in 2022 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 891.5% in 2024, down 6043.33% in 2024.
- Tracing XERS's Change in Receivables over 5 years: stood at $3.3 million in 2022, then sank by 304.38% to -$6.8 million in 2023, then jumped by 89.32% to -$723000.0 in 2024, then sank by 273.58% to -$2.7 million in 2025, then surged by 294.19% to $5.2 million in 2026.
- The last three Change in Receivables figures came in at $5.2 million (Q1 2026), -$2.7 million (Q4 2025), and $703000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Jun 30, 2026 | 1.81 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -2.70 Mn |
| Dec 31, 2025 | -2.70 Mn |
| Sep 30, 2025 | 703,000.00 |
| Sep 30, 2025 | 703,000.00 |
| Jun 30, 2025 | 6.72 Mn |
| Jun 30, 2025 | 6.72 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | -723,000.00 |
| Dec 31, 2024 | -723,000.00 |
| Sep 30, 2024 | -1.30 Mn |
| Sep 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | 5.03 Mn |
| Mar 31, 2024 | -1.78 Mn |
| Mar 31, 2024 | -1.78 Mn |